Search results for "ADULT"

showing 10 items of 17453 documents

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immuno…

2018

A higher capacity to grow under hypoxic conditions can lead to a more aggressive behavior of tumor cells. Determining tumor activity under hypoxia may identify chronic lymphocytic leukemia (CLL) with aggressive clinical course and predict response to chemo-immunotherapy (CIT). A metabolic score was generated by determining pyruvate kinase and lactate dehydrogenase, key enzymes of glycolysis, ex vivo in primary CLL samples under normoxic and hypoxic conditions. This score was further correlated with clinical endpoints and response to CIT in 96 CLL patients. 45 patients were classified as metabolic high risk (HR), 51 as low risk (LR). Treatment-free survival (TFS) was significantly shorter in…

0301 basic medicineOncologyMaleChronic lymphocytic leukemiaHigh-risklcsh:Medicinechemistry.chemical_compoundRisk FactorsClinical endpointGlycolysisAged 80 and overlcsh:R5-920Hazard ratioGeneral MedicineMiddle AgedPrognosisFemaleImmunotherapymedicine.symptomIGHV@lcsh:Medicine (General)GlycolysisResearch PaperAdultmedicine.medical_specialtyLDHGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciencesLactate dehydrogenaseInternal medicinemedicineBiomarkers TumorHumansPK M2AgedProportional Hazards Modelsbusiness.industrylcsh:RHypoxia (medical)medicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyMetabolismchemistryMutationTumor HypoxiabusinessEx vivoCLLEBioMedicine
researchProduct

Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With L…

2020

Contains fulltext : 220040.pdf (Publisher’s version ) (Closed access) BACKGROUND & AIMS: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, CRCs can develop via different pathways. We studied associations between Lynch syndrome-associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC and CTNNB1 in tumors in an international cohort of patients. METHODS: We combined clinical and molecular data from 3 studies. We obtained clinical data from 2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, or MSH6 from Germany, the Net…

0301 basic medicineOncologyMaleColorectal cancerDNA Mutational Analysisgenetic analysisHEREDITARYcancer riskGUIDELINESDNA Mismatch Repair0302 clinical medicineGermanyTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Prospective Studiesprognostic factorFinlandbeta CateninNetherlandsOutcomePrognostic FactorGastroenterologyGenetic AnalysisColonoscopyMiddle AgedCANCERLynch syndromeCancer Risk3. Good healthDNA-Binding ProteinsDEFICIENCYMutS Homolog 2 Proteinsyöpägeenitoutcome030211 gastroenterology & hepatologyDNA mismatch repairFemaleMutL Protein Homolog 1geenitutkimusAdenomaAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAdenoma3122 CancersAdenomatous Polyposis Coli ProteinINSTABILITYSOCIETYMLH103 medical and health sciencesInternal medicinemedicineMANAGEMENTHumansLynchin oireyhtymäneoplasmspaksusuolisyöpäHepatologybusiness.industryCancernutritional and metabolic diseasesennusteetmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposisdigestive system diseasesMSH6030104 developmental biologyMSH2Mutationbusiness
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

Association study of MMP8 gene in osteoarthritis.

2016

Objectives: Osteoarthritis (OA) is a joint disease common in the elderly. There is a prior functional evidence for different matrix metalloproteinases (MMPs), such as MMP8 and MMP9, having a role in the breakdown of cartilage extracellular matrix in OA. Thus, we analyzed whether the common genetic variants of MMP8 and MMP9 contribute to the risk of OA. Materials and methods: In total, 13 common tagging single-nucleotide polymorphisms (SNPs) were studied in a discovery knee OA cohort of 185 cases and 895 controls. For validation, two knee OA replication cohorts and two hand OA replication cohorts were studied (altogether 1369 OA cases, 4445 controls in the five cohorts). The chi(2) test for …

0301 basic medicineOncologyMaleLinkage disequilibriumLINKAGE DISEQUILIBRIUMMATRIX METALLOPROTEINASESOsteoarthritisSUSCEPTIBILITYBioinformaticsMMP8BiochemistryOrthopedics and Sports MedicineIN-VIVOta3141Middle AgedOsteoarthritis Knee3142 Public health care science environmental and occupational healthmedicine.anatomical_structureMatrix Metalloproteinase 8CohortFemaleEXPRESSIONAdultmedicine.medical_specialtySingle-nucleotide polymorphismKNEE OSTEOARTHRITISta3111Polymorphism Single NucleotideAssociationANKLE JOINTS03 medical and health sciencesRheumatologyInternal medicinemedicineSNPHumansgeneMolecular BiologyGeneAgedbusiness.industryCartilageta1184Cell BiologyARTICULAR-CARTILAGEmedicine.diseaseosteoarthritis030104 developmental biologyWIDE STATISTICAL SIGNIFICANCENEUTROPHIL COLLAGENASE3111 BiomedicinebusinessConnective tissue research
researchProduct

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC

2017

[EN] Background Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods Clinically annotated, resected stage I¿III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is¿>1% for most of the ~150 (13 genes) mutations covered in the multiplex test.…

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisKRAS MUTATIONSGene mutationmedicine.disease_cause0302 clinical medicinemultiplex mutation analysisCarcinoma Non-Small-Cell LungMultiplex mutation analysisPrevalenceMultiplexAnaplastic Lymphoma KinaseHETEROGENEITYAged 80 and overMutationSmokingHematologyMiddle AgedProto-Oncogene Proteins c-metProgression-Free SurvivalOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleKRASPREDICT SURVIVALAdultmedicine.medical_specialtyEGFRCELL LUNG-CANCERPrognosis molecular stagingprognosis molecular stagingEGFR KRAS PIK3CAVALIDATION03 medical and health sciencesYoung AdultInternal medicineMultiplex polymerase chain reactionmedicineKRASTYROSINE KINASE INHIBITORSHumansProgression-free survivalLung cancerAgedNeoplasm Stagingbusiness.industryMICROBIOLOGIAADENOCARCINOMAAMPLIFICATIONPIK3CAmedicine.disease030104 developmental biologynon-small-cell lung cancerMutationOVEREXPRESSIONbusinessMultiplex Polymerase Chain ReactionNon-small-cell lung cancerAnnals of Oncology
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospectiv…

2017

Natural Killer cells (NK) are lymphocytes with the potential to recognize and lyse cells which escaped T-cell mediated lysis due to their aberrant HLA expression profiles. Killer cell immunoglobulin-like receptors (KIR) influence NK-cell activity by mediation of activating or inhibitory signals upon interaction with HLA-C (C1, C2) ligands. Therefore, absence of ligands for donor inhibitory KIRs following hematopoietic stem cell transplantation (HSCT) may have an influence on its outcome. Previous studies showed that C1 negative patients have a decreased HSCT outcome. Our study, based on a cohort of 200 C1-negative patients, confirmed these findings for the endpoints: overall survival (OS: H…

0301 basic medicineOncologyMaleMyeloidCell Transplantationmedicine.medical_treatmentlcsh:MedicineHematopoietic stem cell transplantationNK cellsLigandsCohort StudiesWhite Blood Cells0302 clinical medicineMathematical and Statistical TechniquesReceptors KIRCell SignalingComplement C1Animal CellsMedicine and Health SciencesBlood and Lymphatic System ProceduresMembrane Receptor SignalingReceptorlcsh:ScienceBone Marrow TransplantationMultidisciplinaryT CellsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationMiddle AgedImmune Receptor Signaling3. Good healthKiller Cells Naturalmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsCohortPhysical SciencesFemaleCellular TypesUnrelated DonorsStatistics (Mathematics)Research ArticleSignal TransductionAdultmedicine.medical_specialtyAdolescentImmune CellsImmunologySurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesYoung AdultInternal medicinemedicineConfidence IntervalsHumansClinical significanceddc:610Statistical MethodsAgedRetrospective StudiesTransplantationBlood Cellsbusiness.industrylcsh:RBiology and Life SciencesRetrospective cohort studyCell BiologyMultivariate analysis; Stem cell transplantation; T cells; Bone marrow transplantation; NK cells; Hematopoietic stem cell transplantation; Immune receptor signalingTransplantation030104 developmental biologyImmunologyMultivariate Analysislcsh:QbusinessMathematics030215 immunologyStem Cell TransplantationPLoS ONE
researchProduct